Aroma profoundly influences consumer perception of cannabis, yet until now the field has lacked a universally accepted vocabulary to characterize it. According to Tom Shellhammer, professor of food science and technology at Oregon State University, sensory descriptors go beyond merely quantifying THC levels, offering a multi-dimensional perspective akin to those long established in wine and beer industries. Shellhammer asserts that a shared and precise aroma lexicon will bridge the gap between consumers, growers, and retailers by providing a common language to discuss quality more meaningfully.

The impetus for this research lies partly in the limitations of THC concentration as the sole marker for cannabis quality. While high THC is often equated with potency and desirability, it is also associated with adverse health outcomes including impaired cognitive function, cannabinoid hyperemesis syndrome, and acute psychotic episodes. By creating a systematic approach to evaluate aroma, the research suggests a way to shift focus toward sensory quality, potentially mitigating some negative health impacts by encouraging more holistic product assessment protocols.

Drawing parallels from Shellhammer’s extensive research on hops and beer flavor, the study rejects the reductive paradigm of judging products solely by their alcohol or THC content. Historically, both wine and beer industries evolved from similar limitations, eventually embracing aroma, ingredient provenance, and sensory complexity as core quality metrics. This maturation offers a model for cannabis, signaling an era whereby nuanced sensory profiles will complement chemical analyses in defining premium cannabis and hemp products.

Cannabis sativa L. encompasses both hemp and cannabis, classified primarily on THC concentration, with hemp defined by legal limits of 0.3% THC or less. This distinction is crucial for regulatory compliance across U.S. state markets and frames much of the comparative sensory analysis in the study. Both plant types exhibit overlapping aroma characteristics, but with notable differences: cannabis tends to emit skunky, musty, and savory “animalic” notes, while hemp is often described with citrus, fruity, and candy-like fragrances. This divergence underscores the complexity within the species and the need for refined descriptors.

The research engaged a diverse panel of 24 evaluators ranging from ages 21 to 70 and balanced in gender, all with varying degrees of sensory analysis expertise. Importantly, panelists assessed the aroma of raw plant material rather than smoked products, offering a controlled evaluation environment that isolates the inherent aromatic compounds without the confounding influences of combustion or vaporization. This methodological rigor establishes a clean baseline for sensory qualifiers relevant to both scientific inquiry and consumer experience.

Utilizing data collected from Portland’s Cultivation Classic cannabis competitions between 2018 and 2020, researchers formulated a lexicon comprising 25 distinct aroma descriptors. These terms encompass a wide spectrum of olfactory sensations and are designed to be intuitive yet precise, facilitating an accurate and reproducible vocabulary. This foundational lexicon marks a critical step toward standardized sensory evaluation in cannabis science, paralleling the extensive terminologies developed for other aromatic crops and fermented beverages.

Within the scope of this lexicon, the study identified four distinct aroma profiles that characterize hemp and cannabis. Three profiles—fruit, berry, candy; citrus and chemical; and cheesy and vomit/fecal—were predominantly associated with hemp samples. In contrast, a complex fourth profile consisting of funky, earthy, musty, straw, fuel, black tea, woody, and nutty or toasted aromas was more strongly linked to cannabis. These nuanced sensory clusters highlight the rich diversity inherent in cannabis sativa and offer a scaffold for future research and product classification.

Beyond the sensory evaluation, the study investigated the relationship between terpenes and volatile sulfur compounds—two classes of chemicals largely credited with contributing to cannabis aroma. Remarkably, the findings revealed only a weak correlation between the presence of these compounds and the sensory perception articulated by panelists. This insight challenges the common industry assumption that specific terpenes reliably predict particular aromas, underscoring the complexity of cannabis olfaction and emphasizing the need for empirical sensory analysis alongside chemical profiling.

The advent of a standardized aroma lexicon signals an important maturation phase for the cannabis and hemp industries, especially as they transition from an unregulated landscape to more rigorous legal frameworks. By equipping consumers with descriptive tools beyond THC potency and terpene profiles, the industry can promote more informed and nuanced decision making. This evolution mirrors broader trends in food and beverage science, where sensory evaluation is central to quality control, marketing, and consumer education.

The implications of this study extend to public health as well. By shifting emphasis from potency alone to include sensory quality, regulatory bodies and public advocates might better address issues related to overconsumption and adverse effects inherent to high THC products. Offering an aroma-based assessment tool could facilitate the development of products that deliver desired sensory experiences without excessive psychoactive impact, improving both safety and consumer satisfaction.

As research continues, the sensory profiles and descriptive lexicon developed in this study are expected to evolve. Future studies will likely explore expanded sample sizes, regional varietal differences, and the interaction of aroma with other sensory modalities such as flavor and mouthfeel. Also, the integration of advanced analytical chemistry techniques with sensory science could further unravel the complex matrices underlying cannabis aroma, enhancing product characterization and traceability.

This collaborative research, published in the esteemed journal PLOS One, underscores the interdisciplinary nature of cannabis science, bringing together experts in food technology, neurobiology, and sensory analysis. Contributors like neurobiologist Adie Rae add valuable insights bridging the gap between plant chemistry, sensory perception, and potential neurophysiological effects. Such multidisciplinary approaches are critical for establishing cannabis science as a rigorous academic and applied field.

Ultimately, the standardized vocabulary and sensory framework advanced by this research promise to redefine quality assessment in the cannabis and hemp sectors. By moving beyond THC dominance and terpene oversimplification toward a comprehensive sensory lexicon, the industry can foster innovation, improve consumer communication, and pave the way for safer, more enjoyable cannabis experiences. This milestone lays the foundation for an exciting new era where aroma science plays a central role in the future of cannabis.

Subject of Research: Development of a standardized aroma lexicon for cannabis and hemp to improve quality assessment beyond THC potency.

Article Title: Not explicitly stated in the content.

News Publication Date: Not explicitly stated in the content.

Web References:

• https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0335125
• https://www.mdpi.com/2813-1851/1/2/8

References: Research data sourced from Portland’s Cultivation Classic cannabis competitions (2018–2020) and sensory evaluation conducted by Oregon State University.

Image Credits: Oregon State University

Keywords: Cannabis aroma, hemp aroma, sensory lexicon, THC potency, terpene profiles, cannabis quality assessment, sensory analysis, volatile sulfur compounds, Cannabis sativa, cannabis regulation, cannabis research, aroma standardization

The research is comprised of two robust studies, one published recently in JAMA Health Forum and another forthcoming in the American Journal of Health Economics. The initial study rigorously analyzed data encompassing millions of commercially insured individuals from 2007 through 2020, scrutinizing the impact of medical marijuana legalization on opioid prescribing behavior. Strikingly, the findings revealed a consistent 16% decrease in the rate at which patients received opioid prescriptions in states that permitted medical cannabis, underscoring a promising correlation between cannabis legalization and opioid reduction.

This downtrend in opioid prescriptions was not confined to specific demographic segments; instead, it spanned across sexes, age groups, races, and ethnicities, suggesting a broad-based effect of cannabis availability on prescribing practices. Prior research often struggled with heterogeneity in populations and policy contexts, making robust causal inferences challenging. However, this latest work employs sophisticated methodologies designed to infer causality more convincingly, accounting for confounding variables that plague earlier comparative studies between states with and without cannabis laws.

Progressing beyond broad population analyses, the second study narrows focus onto cancer patients—a vulnerable cohort frequently prescribed opioids for pain management. This study uniquely correlates the opening of cannabis dispensaries with measurable decreases not only in the frequency of opioid prescriptions but also in the average duration of prescribed opioid use and the number of prescriptions per patient. These data suggest that tangible access to cannabis through dispensing facilities plays a pivotal role in enabling patients to opt for cannabis-based analgesia over opioids.

Felipe Lozano-Rojas, lead author and assistant professor at the University of Georgia’s School of Public and International Affairs, emphasizes the nuanced application of these findings. While cannabis legalization appears to serve as a valuable harm reduction strategy in the opioid crisis, he cautions against wholesale endorsement of cannabis for all patients in pain without proper medical guidance. The shift away from opioids towards cannabis should be carefully managed within the context of a physician’s recommendation and tailored to the patient’s specific clinical scenario.

The studies further highlight a modest increase in the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin concurrent with the decline in opioids, hinting at a broader transition towards non-opioid pain management modalities. This trend is significant, given the perils associated with opioid therapies, including addiction risk, overdose potential, and mortality. The magnitude and consistency of opioid reduction across diverse subpopulations provide compelling evidence that cannabis can serve as a valuable interventional tool within integrated pain management protocols.

The opioid epidemic has extraordinarily devastated rural communities, where healthcare access challenges exacerbate substance use disorders. This context renders alternative therapies even more urgent. Currently, 39 states and Washington, D.C., have enacted medical cannabis laws for various qualifying conditions, while approximately half the states have legalized cannabis recreationally. This patchwork of legislation creates a natural laboratory for examining how regulatory environments shape prescription patterns and patient outcomes in real-world settings.

Understanding the mechanisms behind the substitution effect observed in the studies is fundamental. Opioids such as hydrocodone, oxycodone, and morphine provide powerful analgesia but carry significant adverse consequences. In contrast, cannabis, while psychoactive, exhibits a markedly lower potential for dependency and lethal overdose. These pharmacological distinctions make cannabis a comparatively safer option for sustained pain control, particularly under clinical supervision.

For cancer patients, who represent a significant proportion of chronic pain sufferers, these findings offer hopeful prospects. Over half of individuals diagnosed with cancer experience substantial pain that often necessitates potent analgesics. By providing accessible cannabis dispensaries, healthcare systems may empower patients to reduce their reliance on opioids, mitigating risks inherent to opioid therapy. The elevation in cannabis availability, especially through dispensaries, appears more influential in opioid reductions than legal statutes alone, indicating that policy implementation and accessibility are key drivers.

Importantly, the JAMA Health Forum study pioneers in establishing a plausible causal link between dispensary openings and opioid reduction specifically within the cancer patient population, an area historically underexamined by health services research. The involvement of interdisciplinary teams spanning public administration, health policy, and clinical research underscores the multifaceted nature of pain management and addiction science.

The implications of these studies extend beyond cancer patients to inform broader public health strategies aiming to curb opioid misuse. Transitioning to non-opioid pain management options like medical cannabis, when done responsibly, may alleviate the strain opioid dependency places on individuals and healthcare systems alike. However, comprehensive patient education, robust clinical guidelines, and ongoing research remain essential to optimize outcomes and minimize potential harms linked to cannabis use.

As the medical and scientific communities continue to unravel the complexities surrounding cannabis and opioid interactions, these promising results advocate for carefully calibrated legal and clinical frameworks that integrate cannabis as a complementary or alternative therapy for pain. This paradigm shift holds the potential not only to transform individual patient care but also to contribute meaningfully to combating the opioid epidemic on a national scale.

Subject of Research: Impact of Cannabis Legalization on Opioid Prescription Patterns in Chronic and Acute Pain Management, Particularly Among Cancer Patients
Article Title: Cannabis Laws and Opioid Use Among Commercially Insured Patients With Cancer Diagnoses
News Publication Date: October 17, 2025
Web References: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2840030?utm_campaign=articlePDF&utm_medium=articlePDFlink&utm_source=articlePDF&utm_content=jamahealthforum.2025.3512, https://www.journals.uchicago.edu/doi/10.1086/738998
Keywords: Psychoactive drugs, Pharmaceuticals, Clinical medicine

The study began with the hypothesis that inhaled cannabis could potentially serve as a therapeutic agent for individuals suffering from asthma and COPD. Researchers were intrigued by anecdotal reports suggesting that some patients experienced relief from their symptoms after using cannabis. Prior to this investigation, however, empirical data on the subject was scarce, leading the team to embark on a comprehensive study aimed at filling this evident gap in knowledge.

Utilizing a robust methodology, the researchers designed a survey to capture a wide array of data concerning participants’ demographics, medical histories, and cannabis usage habits. The survey was disseminated across various platforms, ensuring a broad reach and diverse representation of the population. Participants were asked about their frequency of cannabis use, the mode of consumption—whether through smoking, vaping, or edibles—and the specific respiratory conditions they were facing.

As the data poured in, the research team diligently began to analyze the results. Among the respondents, indications of canna-induced symptom relief were noted, particularly in patients with asthma. This pointed toward the possibility that cannabis might have anti-inflammatory properties, which could theoretically alleviate some respiratory symptoms. However, the findings were not universally positive; the results also raised initial concerns regarding the potential adverse effects of smoking cannabis, particularly in those with pre-existing lung conditions.

A segmented analysis of the data revealed that while some participants reported improved respiratory function and overall quality of life, a considerable percentage experienced negative side effects associated with smoking cannabis. These effects included increased coughing and wheezing, highlighting a critical aspect of the discussion surrounding cannabis and lung health. The dichotomy of results suggests that while some individuals might benefit from inhaled cannabis, others could be exacerbating their conditions—a contentious point that demands further exploration.

In light of these findings, the researchers emphasized the necessity of individualized medicine. They argued that patients considering cannabis as an alternative treatment option should consult healthcare professionals to evaluate potential risks and benefits based on their unique medical backgrounds. This sentiment echoes a broader movement within the medical community towards personalized care, particularly in the context of chronic illness management.

Further complicating the narrative are the varying legal and societal attitudes towards cannabis use across different regions. While some areas have embraced cannabis as a legitimate treatment option, others maintain stringent prohibitions, limiting access for those who could potentially benefit from its therapeutic properties. This discrepancy highlights an urgent need for comprehensive policies that consider the nuances of cannabis usage in clinical practice, particularly for respiratory illnesses.

Moreover, the researchers pointed out the pressing need for longitudinal studies to track the long-term effects of inhaled cannabis on respiratory health. The current study provided a snapshot in time, but further research could illuminate the potential risks or benefits that might emerge as individuals navigate cannabis usage over extended periods. As the landscape of cannabis research evolves, the medical community must remain vigilant in examining emerging evidence and adapting treatment protocols accordingly.

The results of this study are sure to ignite debate among practitioners and patients alike. Cannabis remains a polarizing subject within healthcare, with strong arguments on both sides regarding its efficacy as a medicine. Healthcare professionals are urged to remain informed on the latest findings as more patients turn to alternative remedies for their chronic conditions. As the conversation around cannabis grows, the role of healthcare providers in guiding patient choices becomes increasingly important.

Public health officials and policymakers are likewise encouraged to consider the implications of this research when developing guidelines surrounding cannabis use, especially for respiratory conditions. Given the increasing prevalence of asthma and COPD worldwide, informed, evidence-based strategies will be paramount in managing these chronic diseases effectively.

In conclusion, the study conducted by Rustagi, Jeffers, Graham, and colleagues serves as a significant contribution to the field of respiratory medicine and the ongoing discourse surrounding cannabis use. While the findings indicate potential benefits for some individuals, they also underscore the importance of caution and thorough consultation. Ultimately, this research reinforces the notion that cannabis may not be a panacea; rather, it may serve as an important therapeutic consideration that warrants careful evaluation on a case-by-case basis.

As the world continues to navigate the complex intersections of cannabis, health, and illness, research like this will be pivotal in shaping informed discourse and guiding responsible policy-making. The call for more rigorous clinical trials and longitudinal studies is loud and clear, as the medical community seeks to better understand the role of cannabis in chronic respiratory conditions.

Subject of Research: Inhaled Cannabis and its impact on asthma and COPD

Article Title: Inhaled Cannabis, Asthma, and Chronic Obstructive Pulmonary Disease: A Population-Based Cross-Sectional Study

Article References:

Rustagi, A.S., Jeffers, A.M., Graham, F.J. et al. Inhaled Cannabis, Asthma, and Chronic Obstructive Pulmonary Disease: A Population-Based Cross-Sectional Study of n = 379,049. J GEN INTERN MED (2025). https://doi.org/10.1007/s11606-025-09833-8

Image Credits: AI Generated

DOI: 10.1007/s11606-025-09833-8

Keywords: Inhaled cannabis, asthma, chronic obstructive pulmonary disease, respiratory health, personalized medicine, public health policy

Cannabis consumption during pregnancy is an issue shrouded by complexity, mired in evolving legislation, cultural attitudes, and often conflicting scientific evidence about its potential risks and consequences. The study by Skelton, Iobst, and Benjamin-Neelon meticulously documents how obstetricians, midwives, and other prenatal care providers in the United States navigated the intricate terrain of cannabis advice in clinical encounters. Between 2017 and 2021, a period marked by rapid changes in cannabis policy, the frequency, content, and tone of cannabis-related counseling during prenatal visits shifted substantially. These temporal trends carry profound implications for maternal and fetal health.

Central to interpreting this research is an appreciation of the historical context underpinning cannabis use in pregnancy. Prior to increasing legislative liberalization, cannabis was widely prohibited and stigmatized, often deterring open conversations in healthcare settings. However, as more states moved to legalize both medical and recreational cannabis, patient disclosure increased, compelling healthcare providers to address this issue more explicitly. The 2017–2021 timeframe captures this pivotal transition, allowing investigators to explore how prenatal care providers adapted their communication strategies in response to changing patient behaviors and societal norms.

The findings bring to the forefront a heterogeneous landscape of provider advice. While some clinicians consistently warned against cannabis use due to potential adverse outcomes—such as low birth weight, preterm birth, and neurodevelopmental impacts—others adopted a more nuanced or less assertive approach. This variability reflects both gaps in definitive clinical evidence and differences in provider training, personal beliefs, and institutional guidelines. Notably, the study uncovers disparities tied to geographic region, provider specialty, and patient demographics, all of which influence the likelihood and framing of cannabis-related discussions during prenatal care.

Underpinning these divergent counseling approaches is the complex pharmacology of cannabis and its active compounds, primarily tetrahydrocannabinol (THC) and cannabidiol (CBD). THC readily crosses the placental barrier, exposing the developing fetus to psychoactive substances that may interfere with neurodevelopmental trajectories. Moreover, the endocannabinoid system, which regulates various physiological processes during pregnancy, can be disrupted by exogenous cannabinoids, potentially compromising placental function and fetal growth. The science regarding long-term developmental sequelae remains emergent, fueling the uncertainty and contradictory messaging observed among providers.

In this clinical ambiguity, the study highlights a critical need for standardized, evidence-based guidelines on cannabis counseling in prenatal care. The absence of uniform protocols exacerbates disparities and may undermine patient trust and compliance. Healthcare providers often grapple with balancing the imperative to caution against potential harms while respecting patient autonomy and acknowledging the limited robustness of existing research. This dilemma is further complicated by concurrent substance use and socioeconomic determinants that influence cannabis consumption patterns in pregnant populations.

Importantly, the study reveals that providers increasingly incorporate harm reduction strategies rather than absolute abstinence messaging. This pragmatic approach acknowledges the realities of cannabis use, seeking to minimize fetal exposure by advising avoidance of smoking and recommending cessation at any point during pregnancy. It underscores the evolution of prenatal counseling from paternalistic admonitions to patient-centered dialogues, albeit with considerable variability in execution. Such shifts may be reflective of broader trends in medical communication and public health ethics.

The temporal analysis also coincides with the COVID-19 pandemic era, which dramatically altered healthcare delivery and patient behaviors. These disruptions could have influenced both cannabis use during pregnancy and provider counseling frequency or modalities, including telehealth encounters. The study’s comprehensive dataset allows consideration of these external factors and their interplay with persistent issues such as limited appointment times, provider discomfort, and the stigma associated with substance use disclosure.

Another salient aspect involves the intersectionality of cannabis advice with health equity. Populations disproportionately affected by adverse pregnancy outcomes and socio-economic challenges may also experience differential access to accurate, culturally sensitive counseling. The research reveals that marginalized groups may receive less comprehensive advice concerning cannabis risks, amplifying existing disparities. This underscores the necessity of integrating equity-focused training and resources into prenatal care curricula and public health initiatives.

From a policy perspective, these findings resonate beyond individual clinical encounters. They call for harmonized public health messaging that bridges the gap between rapidly evolving cannabis laws and evidence-based maternal-fetal health guidance. Regulatory bodies and professional organizations must collaborate to produce clear, actionable recommendations that can be uniformly adopted, reducing confusion among providers and patients alike while promoting safer pregnancy outcomes.

Moreover, the study urges further scientific inquiry to resolve enduring knowledge gaps. Longitudinal and mechanistic research is vital to elucidate causal pathways between prenatal cannabis exposure and child neurodevelopment, behavioral health, and metabolic outcomes. Such data will equip clinicians with a firmer foundation to deliver precise advice and improve patient counseling efficacy. Ongoing surveillance of cannabis use trends in pregnancy and their clinical counseling responses remains imperative as new cannabis products and delivery methods emerge.

This research also dovetails with a growing awareness of the nuanced societal dimensions influencing cannabis use in pregnancy. Factors such as mental health, chronic pain, nausea, and historical distrust in healthcare systems contribute to cannabis reliance during gestation. Prenatal counseling must thus extend beyond simplistic prohibitive messages and encompass holistic evaluations that address underlying motivations and barriers to cessation, facilitating tailored support and referrals to addiction and behavioral health services when necessary.

Technological innovations also offer promising avenues to enhance cannabis counseling. Integrating electronic health record prompts, decision-support tools, and provider education modules can augment the consistency and quality of prenatal cannabis advice. Digital platforms tailored for pregnant individuals may provide supplemental information, normalize discussions, and encourage shared decision-making. The study’s insights highlight an urgent need to leverage these tools to address the documented fragmentation and variability.

In retrospect, the study by Skelton and colleagues marks a significant contribution in illuminating the complex clinical landscape surrounding prenatal cannabis counseling in an era of changing societal norms and regulatory frameworks. It provides a nuanced mapping of provider behaviors and highlights domains requiring urgent attention—from standardizing clinical guidelines and enhancing research efforts to fostering equity and patient-centered care. Ultimately, these findings underscore the crucial role of prenatal healthcare providers as mediators of knowledge and influencers of health behaviors amid a rapidly evolving public health challenge.

The implications resonate far beyond the clinic walls. As cannabis legalization proliferates worldwide, the findings hold relevance not only for U.S. policymakers and clinicians but also for global health communities grappling with similar dilemmas. They reaffirm the necessity of interdisciplinary collaboration—uniting obstetrics, addiction medicine, public health, pharmacology, and ethics—to craft responsive, evidence-driven approaches that safeguard the health of mothers and their children in this new era.

As public interest in cannabis use during pregnancy continues to grow, amplified by pervasive social media discourse and changing cultural attitudes, the study’s revelations are especially timely. They invite continued vigilance, critical appraisal, and responsible communication to navigate an issue where science, policy, and personal choice intertwine in deeply complex ways. The evolving narrative around cannabis in prenatal care encapsulates broader challenges of integrating emerging substance use concerns into trusted medical frameworks—an endeavor that demands rigor, sensitivity, and sustained commitment.

Subject of Research: Cannabis-related counseling during prenatal care visits in the United States from 2017 to 2021

Article Title: Cannabis advice occurring at prenatal care visits in the United States, 2017–2021

Article References:
Skelton, K.R., Iobst, S. & Benjamin-Neelon, S.E. Cannabis advice occurring at prenatal care visits in the United States, 2017–2021. J Perinatol (2025). https://doi.org/10.1038/s41372-025-02331-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41372-025-02331-z

The study, published in JAMA Internal Medicine, reveals not only an increase in overall use but a transformation in the demographic profile of older cannabis users. In recent years, those engaging with marijuana in this age bracket are more frequently college-educated, married, female, and higher income earners. This change diverges from earlier patterns where younger, predominantly male populations comprised the majority of cannabis users. These trends point toward shifting social norms and the growing acceptance of cannabis as part of wellness or medical regimens among seniors.

This escalation in marijuana use among older adults is dramatically illustrated by the increase from 4.8 percent in 2021 to 7 percent in 2023—an approximate 46 percent rise in just two years. Such rapid growth warrants attention from clinicians and policymakers alike, given the unique physiological and pharmacological considerations of cannabis in an aging population. The study’s authors attribute part of this rise to the fact that earlier surveys could only effectively measure past-year use; the recent availability of more extensive data enabled an analysis of "past-month" or current use patterns, unveiling a more acute picture of usage frequency.

The increased prevalence of cannabis use among older adults is also influenced by legislative changes across the United States. Currently, most Americans reside in states where marijuana legalization permits medical, recreational, or both types of use. This expanded legal framework has likely contributed to enhanced availability, greater social acceptability, and reduced stigma, making cannabis more approachable to a traditionally conservative cohort. These factors collectively facilitate an environment in which older adults feel more comfortable exploring cannabis as a therapeutic or recreational option.

In addition to demographic shifts, the study highlights that cannabis use rose especially sharply among married seniors, white individuals, those with college degrees, and individuals earning $75,000 or more annually. Notably, older women demonstrated one of the most pronounced increases in cannabis use, although men in this age bracket remain more frequent users overall. These observations underscore a nuanced landscape in which social determinants such as marital status, education, race, and income interplay to influence patterns of substance use.

A particularly compelling aspect of the research is the marked increase in cannabis use among older adults managing chronic diseases. This includes individuals contending with multiple chronic conditions such as cardiovascular ailments, diabetes, hypertension, cancer, and chronic obstructive pulmonary disease (COPD). The uptick may reflect growing interest in cannabis as a potential palliative agent for symptom management, including pain relief and appetite stimulation, within this vulnerable subgroup. However, the biomedical implications demand careful scrutiny as cannabis can interact pharmacodynamically with other medications and may exacerbate certain health conditions if misused.

The research team cautions that some of the observed rise may also be attributed to a cohort effect, wherein individuals who used cannabis earlier in life have aged into the 65-plus demographic. Nonetheless, the steep and rapid escalation in usage percentages within a short timeframe suggests broader cultural and medical acceptance rather than a simple shift of users aging into the bracket. This pattern prompts calls for healthcare providers to more proactively screen for cannabis use and to educate older patients on the potential risks, especially given age-related changes in metabolism and drug sensitivity.

Physiological changes in older adults can significantly affect the metabolism and effects of psychoactive substances like cannabis. Alterations in liver function, changes in body composition, and decreased renal clearance can modify pharmacokinetics, potentially intensifying or prolonging the psychoactive and physiological impacts of cannabinoids. Therefore, the growing prevalence of cannabis use in the elderly necessitates updated clinical guidelines to ensure safe and informed consumption, particularly for patients with polypharmacy or multiple comorbidities.

Joseph Palamar, PhD, MPH, an associate professor at NYU Grossman School of Medicine and the study’s senior author, points to income-based disparities in cannabis use trends. While highest income groups initially displayed the lowest cannabis use prevalence in 2021, by 2023, this same group reported the highest usage rates. This shift may symbolize increased financial access to medical cannabis products, which can be costly and are often not covered by insurance. Consequently, affluence becomes a key determinant of who benefits from emerging cannabis therapies and legal markets.

Geographically, cannabis consumption patterns closely follow state-level regulatory environments. Older adults residing in states with legalized medical marijuana demonstrated higher rates of use than those in states where cannabis remains restricted. This geographic variability reflects the influence of legislative frameworks on drug accessibility and social acceptability. Moreover, it hints at how regulatory landscapes may shape public health outcomes as certain regions become hotspots for cannabis-related healthcare considerations in elderly populations.

From a clinical perspective, there is an urgent need for geriatricians and primary care practitioners to stay apprised of the evolving trends and risks associated with cannabis use in seniors. Benjamin Han, MD, MPH, associate professor at UC San Diego and the first author of the study, emphasizes that cannabis use can complicate the management of chronic diseases and entail risks if patients are uninformed about proper dosing, potential side effects, and drug interactions. As cannabis products diversify and legalization spreads, evidence-based clinical protocols to support aging patients are more critical than ever.

The research received support from the National Institute on Drug Abuse and the UC San Diego Sam and Rose Stein Institute for Research on Aging, underscoring the importance of dedicated funding for studies at the intersection of substance use and aging. Given the rapidly changing landscape of cannabis use and regulation, ongoing surveillance, longitudinal analyses, and in-depth biomedical research will be essential to fully characterize the benefits and risks for this expanding cohort of cannabis consumers.

As the older adult population continues to grow alongside increasing cannabis legalization, understanding the implications of this trend is vital. It poses opportunities for novel symptom management strategies but simultaneously demands cautious integration into clinical practice. The convergence of demographic shifts, legislative changes, and evolving public attitudes marks this phenomenon as a critical area for health policy, gerontology, and addiction medicine research moving forward.

Subject of Research: People
Article Title: Trends in Past-Month Cannabis Use Among Older Adults
News Publication Date: 2-Jun-2025
Web References:

• Center for Drug Use and HIV/HCV Research (CDUHR) at NYU — https://www.cduhr.org/
• National Survey on Drug Use and Health analysis — https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2025.1156
• Pew Research on marijuana legalization — https://www.pewresearch.org/short-reads/2024/02/29/most-americans-now-live-in-a-legal-marijuana-state-and-most-have-at-least-one-dispensary-in-their-county/
  References:
• JAMA Internal Medicine article DOI: 10.1001/jamainternmed.2025.1156
• Historical trends in older adult cannabis use: https://onlinelibrary.wiley.com/doi/10.1111/add.13670
  Keywords: Cannabis, Substance abuse, Aging populations, Geriatrics, Older adults